Results 191 to 200 of about 122,423 (305)

α-Lipoic acid suppresses p53 by preventing annexin A2 degradation to protect dopaminergic neurons in a Parkinson's disease model. [PDF]

Front Neurosci
Liu Y, Sun W.
europepmc   +1 more source

Deep Brain Stimulation and Pregnancy: A Case Report and Literature Review

Movement Disorders Clinical Practice, EarlyView.
Verónica Cabreira, Maria José Rosas
wiley   +1 more source

Living with the Unknown: Intolerance of Uncertainty in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is marked by pervasive uncertainty due to fluctuating motor and non‐motor symptoms, variable treatment response, and an unpredictable clinical course. Intolerance of uncertainty (IU), a tendency to perceive ambiguity as threatening and respond with worry, avoidance, or decisional paralysis, may be ...
Bradley McDaniels, Gregory M. Pontone, Kuhan Pushparatnam, Indu Subramanian   +3 more
wiley   +1 more source

Synaptic effects of interleukin-6 on human iPSC-derived dopaminergic neurons. [PDF]

Neuropsychopharmacology
Huang Y, Michalski C, Zhou Y, Xu C, Niu W, Lucido MJ, Wang J, Feng Y, Miller AH, Wen Z.   +9 more
europepmc   +1 more source

Placebo Effect in Levodopa‐Induced Dyskinesia: A Systematic Review and Meta‐Analysis

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Levodopa‐induced dyskinesia (LID) is a complication of Parkinson's disease (PD) treatment. While the placebo effect is a known component in PD clinical trials, its specific magnitude in the context of LID is not well characterized.
Luiz Vinicius Silva Correa, Alexandre Martins do Nascimento, Bruno Lopes Santos‐Lobato, Henry Mauricio Chaparro‐Solano, Ignacio Fernandez Mata, Vitor Tumas   +5 more
wiley   +1 more source

Remimazolam Ameliorates Autistic-Like Behaviors via Suppression of Ferroptosis in VTA Dopaminergic Neurons in a Mouse Model of ASD. [PDF]

Adv Sci (Weinh)
Zhang Y, Lin J, Tong C, Fu X, Shan M, Huang Y, Zhang K, Zheng J.   +7 more
europepmc   +1 more source

Reduced Dopamine Transporter Uptake in Dentatorubral‐Pallidoluysian Atrophy

Movement Disorders Clinical Practice, EarlyView.
Kei Okuba, Shugo Fujita, Hitoshi Kawasaki, Genko Oyama   +3 more
wiley   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini, Luca Gallo, Arianna Sala, Enza Maria Valente, Micol Avenali, Silvia Paola Caminiti   +5 more
wiley   +1 more source

Neuropeptide S Protects Dopaminergic Neurons in a Paraquat-Induced Parkinson's Model Using SH-SY5Y Cells. [PDF]

Mol Neurobiol
Koçancı FG, Bülbül M, Akçalı İ, Kipmen-Korgun D, Çubukçu E, Aslan MA, Öztüzün A, Akkan SS, Çeker T, Agar A.   +9 more
europepmc   +1 more source

Electrochemical measurements at human iPSC-derived FOXA2 dopaminergic neurons suggest a role for partial release in presynaptic plasticity. [PDF]

QRB Discov
Gu C, Lork A, Majdi S, Rabasco S, Peng H, Ni A, Ernst C, Ewing AG.   +7 more
europepmc   +1 more source